Inclusion Criteria:

          -  Demonstration of understanding and voluntarily signing of an informed consent form

          -  Age ≥ 18 years

          -  Histologically or cytologically documented, incurable or metastatic solid tumor or B
             cell NHL that is refractory to or intolerant of all standard therapy or for which no
             standard therapy is available

          -  Expansion Phase only: Documentation of MYC genomic amplification/overexpression by
             tumor or blood-based analysis.

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1
             (RECIST v1.1). NHL subjects must have bi-dimensionally measurable disease on cross
             sectional imaging by computed tomography (CT) or magnetic resonance imaging (MRI) as
             defined by Lugano criteria (Cheson, Fisher, et al., 2014).

          -  Adequate organ function

          -  Females of childbearing age must not be pregnant at time of Screening/beginning of
             treatment and agree to either abstain from sexual intercourse or use highly effective
             methods of contraception (for up to 3 months after last dose of study drug)

          -  Males sexually active with a woman of childbearing age must agree to use barrier
             method of birth control during and after the study (up to 3 months after last dose of
             study drug)

        Exclusion Criteria:

          -  Life expectancy <3 months, as determined by the Investigator.

          -  Treatment with any local or systemic antineoplastic therapy (including chemotherapy,
             hormonal therapy, or radiation) within 3 weeks prior to first dose of BTX-A51

          -  Chronic use of corticosteroids in excess of 10 mg daily of prednisone or equivalent
             within 4 weeks prior to first dose of BTX-A51

          -  Major trauma or major surgery within 4 weeks prior to first dose of BTX-A51.

          -  Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤1
             except for alopecia or Grade ≤2 immunotherapy-related thyroid toxicity.

          -  History of, or known, central nervous system (CNS) disease involvement, or prior
             history of NCI CTCAE Grade ≥3 drug-related CNS toxicity.

          -  Clinically significant cardiac disease

          -  Active uncontrolled systemic fungal, bacterial, mycobacterial, or viral infection

          -  Known positive test result for human immunodeficiency virus (HIV) or acquired immune
             deficiency syndrome (AIDS)

          -  Active hepatitis C virus (HCV) or hepatitis B virus (HBV)

          -  Second primary malignancy that has not been in remission for greater than 3 years

          -  Any serious underlying medical (e.g., pulmonary, renal, hepatic, gastrointestinal, or
             neurological) or psychiatric condition (e.g., alcohol or drug abuse, dementia or
             altered mental status) or any issue that would limit compliance with study
             requirements

          -  Pregnant, lactating, or breastfeeding.

          -  Participation or plans to participate in another interventional clinical study.